Patients With Specific Types of Lipids May Be at Higher Risk of Developing Blinding Eye Disease

Principal Investigator: Louis R. Pasquale, MD, FARVO, Deputy Chair for Ophthalmology Research for the Mount Sinai Health System Co-First Authors: Oana A. Zeleznik, PhD, Instructor in Medicine at Brigham and Women’s Hospital and Jae H. Kang, ScD, Assistant Professor of…

AI Used to Advance Drug Delivery System for Glaucoma and Other Chronic Diseases

Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have used artificial intelligence models and machine-learning algorithms to successfully predict which components of amino acids that make up therapeutic proteins are most likely to safely deliver therapeutic drugs to animal eye cells.

King Chulalongkorn Memorial Hospital Doctors Suggest Ways to Prevent Glaucoma through Early Detection

The Excellence Center for Glaucoma, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, and Thai Glaucoma Society encourage all of us to realize the significance of glaucoma as it is the world’s number 1 cause of irreversible blindness. In Thailand, over 2 million people are affected by glaucoma.

ARVO Foundation Names 2023 Winners of Dr. David L. Epstein Award

The Association for Research in Vision and Ophthalmology (ARVO) announced today the 2023 recipients of the Dr. David L. Epstein Award:Since 2016, the Dr. David L. Epstein Award has been given annually to a well-established senior investigator with a documented history of conducting eye and vision research in glaucoma and of mentoring clinician-scientists to independent academic and research careers.

ARVO Foundation Announces Recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

The Association for Research in Vision and Ophthalmology (ARVO) Foundation announced today the recipients of the 2023 Pfizer Ophthalmics Carl Camras Translational Research Award:Granted annually to young investigators working in areas of translational research, each recipient will be awarded $12,000.

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

Bausch + Lomb, a leading global eye health company, and Glaucoma Research Foundation a non-profit organization with the vision of curing glaucoma, today announced the launch of ‘Screen, Protect, Cure,’ a campaign designed to provide educational resources and raise awareness of glaucoma.

Research to Prevent Blindness Marks $400 Million in Funding to Advance Eye Disease Research

Research to Prevent Blindness announces a new round of awardees who are generating critical knowledge around a host of sight-threatening conditions. With this latest round of funding, RPB has provided more than $400 million in research funding.

UC Davis Health opens doors to new state-of-the-art eye care facility in Sacramento

UC Davis Health welcomed the first patients to the new Ernest E. Tschannen Eye Institute on Monday, Dec. 5. The state-of-the-art facility, which houses both clinicians and researchers, is dedicated to advancing world-class eye care and offering hope for sight restoration.

3D map reveals DNA organization within human retina cells

National Eye Institute researchers mapped the organization of human retinal cell chromatin, the fibers that package 3 billion nucleotide-long DNA molecules into compact structures that fit into chromosomes within each cell’s nucleus. The resulting comprehensive gene regulatory network provides insights into regulation of gene expression in general, and in retinal function, in both rare and common eye diseases. The study published in Nature Communications.

Early onset of diabetes, hypertension can predict early glaucoma, UTSW ophthalmologists report

The earlier individuals develop Type 2 diabetes or hypertension in life, the earlier they are likely to develop primary open-angle glaucoma (POAG), the leading cause of irreversible blindness worldwide, researchers from UT Southwestern reported in a recent study. The findings, published in Clinical Ophthalmology, could lead to better screening protocols for POAG, which accounts for up to 90% of all cases of glaucoma.

Scientists Uncover Role of Alzheimer’s-Linked APOE Gene in Glaucoma Protection and Identify Promising Treatment Strategy to Prevent Vision Loss

Scientists have demonstrated that the APOE4 gene variant, which increases risk for Alzheimer’s but decreases risk of glaucoma in humans, blocks a disease cascade that leads to the destruction of retinal ganglion cells in glaucoma. Additionally, they showed in mouse models that the death of retinal ganglion cells – the cause of vision loss in glaucoma – can be prevented by using medications to inhibit a molecule called Galectin-3, which is regulated by the APOE gene. These findings taken together emphasize the critical role of APOE in glaucoma and suggest that Galectin-3 inhibitors hold promise as a glaucoma treatment, according to the authors.

High-Tech Imaging Offers New Way to Detect Signs of Early Glaucoma

Mount Sinai study shows flavoprotein fluorescence could serve as new biomarker

Black Patients Found Six Times More Likely to Have Advanced Vision Loss After Glaucoma Diagnosis Than White Patients

Black patients have a dramatically higher risk of advanced vision loss after a new diagnosis of primary open angle glaucoma (POAG) when compared to white patients, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE).

UIC researchers find evidence of possible link between herpes simplex and neurogenerative diseases

A new study by researchers at University of Illinois Chicago suggests that when the protein optineurin, or OPTN, is present in cells it restricts the spread of HSV-1, the herpes simplex virus type 1.In a “first of its kind” study, researchers also found a potential direct connection between neurodegenerative diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), glaucoma, and the herpesvirus.

Research to Prevent Blindness and Association of University Professors of Ophthalmology Announce 2022 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

Donald Zack, MD, PhD, is recognized for ground-breaking contributions to the field of vision research, funded by Research to Prevent Blindness, an anonymous donor, and the Association of University Professors of Ophthalmology.

High Caffeine Consumption may be Associated with Increased Risk of Blinding Eye Disease

Frequent caffeine intake could more than triple risk of glaucoma for those genetically predisposed to higher eye pressure

Research to Prevent Blindness and The Glaucoma Foundation Offer Critical Funding for Early-Career Vision Scientists

Research to Prevent Blindness and The Glaucoma Foundation are pleased to announce a new round of grants, the Career Advancement Awards (CAAs), that support early-career researchers as they seek new knowledge related to eye diseases.

New Fellowships Support Under-Represented Minorities in Glaucoma Research

The Glaucoma Foundation (TGF) and Research to Prevent Blindness (RPB) have partnered to launch a new grant aimed at supporting under-represented racial and ethnic minority researchers in the pursuit of glaucoma research. The TGF (sponsored by Patricia Hill) / RPB Fellowships in Glaucoma provide one-year, $10,000 fellowships focused on substantive glaucoma research.

New York Eye and Ear Infirmary of Mount Sinai Celebrates 200th Anniversary and Honors its Pioneering Black Physician

Hosts Dedication for a Former Slave Who Became Country’s First African American Eye and Ear Specialist